Risk Factors for Multidrug Resistant Tuberculosis in Europe: a Systematic Review

Overview

Journal Thorax

Date 2005 Oct 29

PMID 16254056

Citations 174

Authors

A Faustini

A J Hall

C A Perucci

Affiliations

Soon will be listed here.

Abstract

Background: The resurgence of tuberculosis (TB) in western countries has been attributed to the HIV epidemic, immigration, and drug resistance. Multidrug resistant tuberculosis (MDR-TB) is caused by the transmission of multidrug resistant Mycobacterium tuberculosis strains in new cases, or by the selection of single drug resistant strains induced by previous treatment. The aim of this report is to determine risk factors for MDR-TB in Europe.

Methods: A systematic review was conducted of published reports of risk factors associated with MDR-TB in Europe. Meta-analysis, meta-regression, and sub-grouping were used to pool risk estimates of MDR-TB and to analyse associations with age, sex, immigrant status, HIV status, occurrence year, study design, and area of Europe.

Results: Twenty nine papers were eligible for the review from 123 identified in the search. The pooled risk of MDR-TB was 10.23 times higher in previously treated than in never treated cases, with wide heterogeneity between studies. Study design and geographical area were associated with MDR-TB risk estimates in previously treated patients; the risk estimates were higher in cohort studies carried out in western Europe (RR 12.63; 95% CI 8.20 to 19.45) than in eastern Europe (RR 8.53; 95% CI 6.57 to 11.06). National estimates were possible for six countries. MDR-TB cases were more likely to be foreign born (odds ratio (OR) 2.46; 95% CI 1.86 to 3.24), younger than 65 years (OR 2.53; 95% CI 1.74 to 4.83), male (OR 1.38; 95% CI 1.16 to 1.65), and HIV positive (OR 3.52; 95% CI 2.48 to 5.01).

Conclusions: Previous treatment was the strongest determinant of MDR-TB in Europe. Detailed study of the reasons for inadequate treatment could improve control strategies. The risk of MDR-TB in foreign born people needs to be re-evaluated, taking into account any previous treatment.

Citing Articles

Risk factors for multidrug resistance in pulmonary tuberculosis patients with diabetes mellitus.

Wu L, Chen N, Xia D, Jiang X Front Med (Lausanne). 2025; 12:1516207.

PMID: 39958828 PMC: 11825338. DOI: 10.3389/fmed.2025.1516207.

Global burden of HIV-negative multidrug- and extensively drug-resistant tuberculosis based on Global Burden of Disease Study 2021.

Chen Y, Chen W, Cheng Z, Chen Y, Li M, Ma L Sci One Health. 2025; 3:100072.

PMID: 39763639 PMC: 11701857. DOI: 10.1016/j.soh.2024.100072.

Prevalence, patterns, and determinants of drug-resistant tuberculosis in Gulf Cooperation Council countries: an updated systematic review.

Alibrahim A, Alqahtani H, Thirunavukkarasu A, Qazi I PeerJ. 2024; 12:e18628.

PMID: 39619190 PMC: 11608559. DOI: 10.7717/peerj.18628.

Audit of risk factors of drug-sensitive, drug-resistant tuberculosis disease, a case-control study of patients registered under NTEP, Gujarat.

Shah V, Yogesh M, Kothari D, Gandhi R, Nagda J J Family Med Prim Care. 2024; 13(9):3614-3620.

PMID: 39464923 PMC: 11504741. DOI: 10.4103/jfmpc.jfmpc_1967_23.

Factors associated with tuberculosis drug resistance among presumptive multidrug resistance tuberculosis patients identified in a DRTB surveillance study in western Kenya.

Okumu A, Orwa J, Sitati R, Omondi I, Odhiambo B, Ogoro J J Clin Tuberc Other Mycobact Dis. 2024; 37:100466.

PMID: 39188352 PMC: 11345928. DOI: 10.1016/j.jctube.2024.100466.

References

Schaberg T, Gloger G, Reichert B, Mauch H, Lode H . Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993. Eur Respir J. 1995; 8(2):278-84. DOI: 10.1183/09031936.95.08020278. View

Gilad J, Borer A, Riesenberg K, Peled N, Schlaeffer F . Epidemiology and ethnic distribution of multidrug-resistant tuberculosis in southern Israel, 1992-1997: the impact of immigration. Chest. 2000; 117(3):738-43. DOI: 10.1378/chest.117.3.738. View

Van Rie A, Warren R, Richardson M, Gie R, Enarson D, Beyers N . Classification of drug-resistant tuberculosis in an epidemic area. Lancet. 2000; 356(9223):22-5. DOI: 10.1016/S0140-6736(00)02429-6. View

Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset J . Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. Int J Tuberc Lung Dis. 2000; 4(7):665-72. View

Helbling P, Altpeter E, Raeber P, Pfyffer G, Zellweger J . Surveillance of antituberculosis drug resistance in Switzerland 1995-1997: the central link. Eur Respir J. 2000; 16(2):200-2. DOI: 10.1034/j.1399-3003.2000.16b03.x. View

Zwolska Z, Augustynowicz-Kopec E, Klatt M . Primary and acquired drug resistance in Polish tuberculosis patients: results of a study of the national drug resistance surveillance programme. Int J Tuberc Lung Dis. 2000; 4(9):832-8. View

Torres L, Arazo P, Blas Perez J, del Pilar Amador M, Lezcano M, Revillo M . [Resistance of Mycobacterium tuberculosis in Zaragoza, Spain (1993-1997) and related factors]. Med Clin (Barc). 2001; 115(16):605-9. DOI: 10.1016/s0025-7753(00)71638-1. View

Hayward A, Herbert J, Watson J . Tuberculosis drug resistance in England and Wales. How much is 'home-grown'?. Epidemiol Infect. 2000; 125(2):463-4. PMC: 2869621. DOI: 10.1017/s0950268899004434. View

Lockman S, Kruuner A, Binkin N, Levina K, Wang Y, Danilovitsh M . Clinical outcomes of Estonian patients with primary multidrug-resistant versus drug-susceptible tuberculosis. Clin Infect Dis. 2001; 32(3):373-80. DOI: 10.1086/318489. View

10.

Espinal M, Laszlo A, Simonsen L, Boulahbal F, Kim S, Reniero A . Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001; 344(17):1294-303. DOI: 10.1056/NEJM200104263441706. View

11.

Teixeira L, Perkins M, Johnson J, Keller R, Palaci M, do Valle Dettoni V . Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001; 5(4):321-8. View

12.

Pfyffer G, Strassle A, van Gorkum T, Portaels F, Rigouts L, Mathieu C . Multidrug-resistant tuberculosis in prison inmates, Azerbaijan. Emerg Infect Dis. 2001; 7(5):855-61. PMC: 2631864. DOI: 10.3201/eid0705.017514. View

13.

Fietta A, Cascina A, Meloni F, Morosini M, Casali L, Bono L . A 10-year survey of Mycobacterium tuberculosis isolates in Pavia and their drug resistance: a comparison with other Italian reports. J Chemother. 2002; 14(1):33-40. DOI: 10.1179/joc.2002.14.1.33. View

14.

Migliori G, Fattorini L, Vaccarino P, Besozzi G, Saltini C, Orefici G . Prevalence of resistance to anti-tuberculosis drugs: results of the 1998/99 national survey in Italy. Int J Tuberc Lung Dis. 2002; 6(1):32-8. View

15.

Toungoussova S, Caugant D, Sandven P, Mariandyshev A, Bjune G . Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis. 2002; 6(5):406-14. View

16.

Djuretic T, Herbert J, Drobniewski F, Yates M, Smith E, Magee J . Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax. 2002; 57(6):477-82. PMC: 1746361. DOI: 10.1136/thorax.57.6.477. View

17.

Spradling P, Nemtsova E, Aptekar T, Shulgina M, Rybka L, Wells C . Anti-tuberculosis drug resistance in community and prison patients, Orel Oblast, Russian Federation. Int J Tuberc Lung Dis. 2002; 6(9):757-62. View

18.

Kilicaslan Z, Albal H, Kiyan E, Aydemir N, Seber E . Drug resistance in pulmonary tuberculosis in Istanbul. Eur J Clin Microbiol Infect Dis. 2002; 21(10):763-4. DOI: 10.1007/s10096-002-0795-0. View

19.

Mester J, Vadasz I, Pataki G, Parsons L, FODOR T, Salfinger M . Analysis of tuberculosis surveillance in Hungary in 2000. Int J Tuberc Lung Dis. 2002; 6(11):966-73. View

20.

Nechaeva O, Skachkova E, FOMINA N . [Drug resistance of Mycobacterium tuberculosis in the Sverdlovsk Region]. Probl Tuberk. 2003; (9):8-11. View